Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
+$0.02 today
- Market cap
- $94.20M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
Volume 2.69M
Average 1.44M
CATX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Perspective Therapeutics, Inc.AMEX: CATX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.13M rose 53.8% year over year, ahead of the +35.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.4% from the prior quarter. Over 3 fiscal years it compounded at +111.4% a year.
Context
- Depreciation & amortization amounted to 367.8% of revenue in FY2025, up 209.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +53.8% holds above the trailing-twelve-month pace of +35.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.25M USD
- Year-over-year change
- +41.0%
- 4-year CAGR
- +90.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.25M | +41.0% |
| FY2024 | 2024-12-31 | 2.31M | +143.8% |
| FY2023 | 2023-12-31 | 946K | +175.0% |
| FY2022 | 2022-12-31 | 344K | +38.7% |
| FY2021 | 2022-06-30 | 248K | — |
Depreciation & Amortization vs competitors
How CATX compares with its peers on the latest reported figures
- CATX's LTM Mar 2026 depreciation & amortization of $3.65M is the 2nd largest of the 5 companies compared; the peer median is $614K.
- Its year-over-year change of +35.4% is the 3rd highest of 5, against a peer median of +32.8%.
- Depreciation & amortization amounts to 589.8% of revenue for CATX, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.43M | +26.3% | +11.3% | 1.0% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
| LTM Mar 2026 | $639K | +39.2% | +7.1% | 2.8% | |
| LTM Mar 2026 | $589K | -20.5% | +16.3% | 1.3% | |
| LTM Mar 2026 | $413K | +120.9% | +38.3% | 0.5% | |
| Peer median (excluding CATX) | $614K | +32.8% | +13.8% | 1.1% | |
Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2022 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.27M) | (14.67M) | (46.51M) | (79.28M) | (103.12M) |
| Depreciation & Amortization | 248K | 344K | 946K | 2.31M | 3.25M |
| Deferred Income Tax | 0 | (1.68M) | (2.65M) | (2.1M) | (793K) |
| Stock-Based Compensation | 1.09M | 1.34M | 3.74M | 5.39M | 8.97M |
| Change in Working Capital | (1.85M) | 338K | 2.3M | 31.81M | 1.68M |
| Accounts Receivables | 405K | 490K | (426K) | 1.05M | (32K) |
| Inventory | (2.67M) | (152K) | 359K | 11K | 0 |
| Accounts Payables | 236K | 0 | 1.58M | 1.89M | 147K |
| Other Working Capital | 182K | (28K) | 779K | 29.74M | 1.57M |
| Other Non-Cash Items | 77K | 472K | 5.27M | 55.39M | 7.53M |
| Operating Cash Flow | (7.71M) | (12.17M) | (36.91M) | (18.29M) | (82.48M) |
| Capital Expenditures | (266K) | (302K) | (1.07M) | (54.41M) | (12.75M) |
| Acquisitions (Net) | 0 | 0 | 2.7M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (243.51M) | (119.84M) |
| Sales of Investments | 0 | 0 | 22.76M | 0 | 173.95M |
| Other Investing Activities | (18K) | (57.38M) | (18K) | 78.99M | (135K) |
| Investing Cash Flow | (284K) | (57.68M) | 24.37M | (218.93M) | 41.23M |
| Debt Repayment | — | — | (68K) | (48K) | (52K) |
| Common Stock Issued | 56K | 0 | 364K | 275.81M | 10.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 56K | 489K | 289.39M | 0 |
| Financing Cash Flow | 56K | 56K | 785K | 289.39M | 10.31M |
| Effect of Forex Changes | 0 | 61.86M | 0 | 0 | 0 |
| Net Change in Cash | (7.94M) | 182K | (46.65M) | 52.16M | (30.95M) |
| Free Cash Flow | (7.98M) | (12.47M) | (37.99M) | (72.71M) | (95.23M) |
Perspective Therapeutics, Inc.
AMEX:CATX
Intrinsic Alpha fair value
Locked
Current Price
$0.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.